Elizabeth Holmes Hones Her Defense in Day 2 of Testimony

But experts have argued that she had no choice but to defend herself, given the evidence presented by prosecutors. That has included text messages that showed Ms. Holmes was aware of Theranos’s technology problems and testimony about faked demonstrations of its abilities. Prosecutors also revealed that after an employee, Erika Cheung, spoke to regulators about problems in the Theranos lab, the start-up hired a private detective to follow her.

“They think they are behind, and they have a smart, likable, young, attractive witness,” Neama Rahmani, the president of the West Coast Trial Lawyers and a former federal prosecutor, said of Ms. Holmes. “And she thinks she’s going to talk her way out of it.”

One key point made by prosecutors was that Theranos could never conduct more than 12 different blood tests on its own machines. It secretly used blood analysis machines from companies like Siemens to run most of its tests, but proclaimed it could do hundreds or thousands at various times.

Ms. Holmes’s lawyers have for weeks tried complicating the prosecution’s narrative. They have pointed to patents created by Theranos. They have hammered investors for not doing enough diligence on the start-up before eagerly writing checks to fund it. And they painted Ms. Holmes as inexperienced and unqualified to run a lab, directing blame for Theranos’s failure at those who were experienced and qualified.

But on the stand, Ms. Holmes presented herself as an impressive and ambitious chief executive when describing the early days of Theranos. She detailed a patent that bore her name for an early concept of the company, as well as the help she got from Channing Robertson, a respected scientist and Stanford University professor who joined Theranos’s board. She was relaxed and confident, smiling widely and nodding before answering questions.

On Monday, her direct examination continued in chronological order. Her lawyers walked through the details of preliminary studies that Theranos had done with a number of drug companies in 2008, 2009 and 2010. They also noted that Theranos’s technology had performed well in those early studies with Merck, AstraZeneca, Centocor, Bristol Myers Squibb and others.

Representatives from Pfizer and Schering-Plough testified earlier that they had evaluated Theranos’s technology and had come away unimpressed.

Yoojin Song: fostering meaningful exchanges between people and digital products

Yoojin Song, a New York-based product designer, brings a creative approach to fostering meaningful exchanges between people and digital products. Her expertise lies in UX design, UI design, and interaction design. She views design as a problem-solving tool and a means to enhance the connection between digital and physical experiences. Her passion for research-driven and human-centered […]

Know More

WhatsApp: A new way to send and receive USDT (without gas fees)

In a bold move that mirrors Telegram’s recent successful launch of their Wallet, WhatsApp’s 3.03 billion users can now seamlessly send and receive USDT through WhatsApp without fees through a beta service launched by tech startup TeekPay. This innovation could reshape how cryptocurrency transactions are conducted, but it also raises significant questions about the long-term […]

Know More

Refresh Your Fitness Routine with freebeat’s AI-Driven Workouts

In today’s digital fitness landscape, many users struggle with content fatigue. Traditional fitness platforms, despite offering a range of workouts with charismatic instructors, often rely on a limited selection of exercise sessions and music tracks. Over time, this can make the content feel repetitive, reducing motivation and engagement. This is where freebeat, with its advanced […]

Know More